Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Gihan Hamdy Elsisi, João L. Carapinha, Rania Afify, Mohamed Abd Elmoty & Mohamed Khalaf. (2020) A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients. Journal of Medical Economics 23:10, pages 1168-1175.
Read now
Read now
Karthik Ramasamy, Sujith Dhanasiri, Howard Thom, Vanessa Buchanan, Suzanne Robinson, Vijay K. D’Souza & Katja Weisel. (2020) Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leukemia & Lymphoma 61:3, pages 668-679.
Read now
Read now
Marscha S Holleman, Harm van Tinteren, Harry JM Groen, Maiwenn J Al & Carin A Uyl-de Groot. (2019) First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis. OncoTargets and Therapy 12, pages 1413-1421.
Read now
Read now
Paul G. Richardson, Sonja Zweegman, Elizabeth K. O’Donnell, Jacob P. Laubach, Noopur Raje, Peter Voorhees, Renda H. Ferrari, Tomas Skacel, Shaji K. Kumar & Sagar Lonial. (2018) Ixazomib for the treatment of multiple myeloma. Expert Opinion on Pharmacotherapy 19:17, pages 1949-1968.
Read now
Read now
Parameswaran Hari, Huamao Mark Lin, Yanyan Zhu, Deborah Berg, Paul G. Richardson & Philippe Moreau. (2018) Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma. Journal of Medical Economics 21:8, pages 793-798.
Read now
Read now
Articles from other publishers (20)
Tung-Lung Yang, Chin Lin, Ching-Liang Ho, Tzu-Chuan Huang, Yi-Ying Wu, Hong-Jie Jhou, Po-Huang Chen & Cho-Hao Lee. (2023) Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review. Life 13:12, pages 2259.
Crossref
Crossref
Jung Yeon Lee, Sung-Soo Park, Young-Woo Jeon, Seung-Hwan Shin, Seung-Ah Yahng & Chang-Ki Min. (2023) Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study. Journal of Cancer Research and Clinical Oncology.
Crossref
Crossref
Cirino Botta, Emilia Gigliotta, Bruno Paiva, Rita Anselmo, Marco Santoro, Paula Rodriguez Otero, Melania Carlisi, Concetta Conticello, Alessandra Romano, Antonio Giovanni Solimando, Claudio Cerchione, Matteo Da Vià, Niccolò Bolli, Pierpaolo Correale, Francesco Di Raimondo, Massimo Gentile, Jesus San Miguel & Sergio Siragusa. (2022) Network meta‐analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant. Hematological Oncology 40:5, pages 987-998.
Crossref
Crossref
Szabolcs Kiss, Noémi Gede, Alexandra Soós, Péter Hegyi, Bettina Nagy, Marcell Imrei, Bernadett Czibere, Nelli Farkas, Lilla Hanák, Zsolt Szakács, Bálint Eröss & Hussain Alizadeh. (2021) Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: A network meta-analysis. Critical Reviews in Oncology/Hematology 168, pages 103504.
Crossref
Crossref
Larisa P. Mendeleeva, Olga M. Votiakova, Irina G. Rekhtina, Evgenii A. Osmanov, Irina V. Poddubnaya, Liudmila Iu. Grivtsova, Natalia A. Falaleeva, Vadim V. Baikov, Alla M. Kovrigina, Aleksei A. Nevol’skikh, Sergei A. Ivanov, Zhanna V. Khailova & Tigran G. Gevorkian. (2021) Multiple myeloma. Journal of Modern Oncology 22:4, pages 6-28.
Crossref
Crossref
Edin Basic, Mathias Kappel, Arpit Misra, Leopold Sellner, Boris A. Ratsch & Dennis A. Ostwald. (2020) Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany. The European Journal of Health Economics 21:9, pages 1351-1361.
Crossref
Crossref
Sotirios Michaleas, Elisabeth Penninga, Doris Hovgaard, Anne-Marie Dalseg, Aldana Rosso, Sinan B. Sarac, Jorge Camarero Jimenez, Lucia López-Anglada Fernández, Carolina Prieto Fernández, Victor Mangas-SanJuan, Isabel Garcia, Concepcion Payares-Herrera, Aranzazu Sancho-López, Harald Enzmann, Marcia Sofia Sanches de Castro Lopes Silva, Sílvia Duarte & Francesco Pignatti. (2020) EMA Review of Daratumumab (Darzalex) for the Treatment of Adult Patients Newly Diagnosed with Multiple Myeloma. The Oncologist 25:12, pages 1067-1074.
Crossref
Crossref
Hélène Gardeney, Arthur Bobin, Cécile Gruchet, Florence Sabirou, Anthony Lévy, Laly Nsiala, Laura Cailly, Cécile Tomowiak, Jose Torregrosa, Niels Moya, Cyrille Hulin, Xavier Leleu & Stéphanie Guidez. (2020) Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients. Journal of Clinical Medicine 9:11, pages 3554.
Crossref
Crossref
Smith Giri, Madan Raj Aryal, Han Yu, Alyssa Grimshaw, Ranjan Pathak, Scott P. Huntington & Binod Dhakal. (2020) Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal of Geriatric Oncology 11:8, pages 1285-1292.
Crossref
Crossref
Maximilian Merz, Tobias Dechow, Mithun Scheytt, Christian Schmidt, Bjoern Hackanson & Stefan Knop. (2020) The clinical management of lenalidomide-based therapy in patients with newly diagnosed multiple myeloma. Annals of Hematology 99:8, pages 1709-1725.
Crossref
Crossref
Manuel David Gil‐Sierra, Vicente Gimeno‐Ballester, Silvia Fenix‐Caballero & Emilio Jesus Alegre‐Del Rey. (2020) Network meta‐analysis of first‐line treatments in transplant‐ineligible multiple myeloma patients. European Journal of Haematology 105:1, pages 56-65.
Crossref
Crossref
Vanessa Piechotta, Tina Jakob, Peter Langer, Ina Monsef, Christof Scheid, Lise J Estcourt, Sunday Ocheni, Sebastian Theurich, Kathrin Kuhr, Benjamin Scheckel, Anne Adams & Nicole Skoetz. (2019) Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Crossref
Yaohua Cao, Ning Wan, Zhuoru Liang, Jingmei Xie, Sen Wang, Tengfei Lin, Tiantian Zhang & Jie Jiang. (2019) Treatment Outcomes in Patients With Newly Diagnosed Multiple Myeloma Who Are Ineligible for Stem-Cell Transplantation: Systematic Review and Network Meta-analysis. Clinical Lymphoma Myeloma and Leukemia 19:8, pages e478-e488.
Crossref
Crossref
Crystal Antoine-Pepeljugoski & Marc Justin Braunstein. (2019) Management of Newly Diagnosed Elderly Multiple Myeloma Patients. Current Oncology Reports 21:7.
Crossref
Crossref
Ioannis Ntanasis-Stathopoulos, Evangelos Terpos & Meletios A. Dimopoulos. (2019) Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. The Cancer Journal 25:1, pages 2-10.
Crossref
Crossref
Paul G. Richardson, Jesus F. San Miguel, Philippe Moreau, Roman Hajek, Meletios A. Dimopoulos, Jacob P. Laubach, Antonio Palumbo, Katarina Luptakova, Dorothy Romanus, Tomas Skacel, Shaji K. Kumar & Kenneth C. Anderson. (2018) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer Journal 8:11.
Crossref
Crossref
Francesca Gay, Graham Jackson, Laura Rosiñol, Sarah A. Holstein, Philippe Moreau, Stefano Spada, Faith Davies, Juan José Lahuerta, Xavier Leleu, Sara Bringhen, Andrea Evangelista, Cyrille Hulin, Ugo Panzani, David A. Cairns, Francesco Di Raimondo, Margaret Macro, Anna Marina Liberati, Charlotte Pawlyn, Massimo Offidani, Andrew Spencer, Roman Hájek, Evangelos Terpos, Gareth J. Morgan, Joan Bladé, Pieter Sonneveld, Jesús San-Miguel, Philip L. McCarthy, Heinz Ludwig, Mario Boccadoro, Maria-Victoria Mateos & Michel Attal. (2018) Maintenance Treatment and Survival in Patients With Myeloma. JAMA Oncology 4:10, pages 1389.
Crossref
Crossref
Derrick Tao & Vinay Prasad. (2018) Choice of control group in randomised trials of cancer medicine: are we testing trivialities?. The Lancet Oncology 19:9, pages 1150-1152.
Crossref
Crossref
Steve Schey, Luis Felipe Casado Montero, Chloe Stengel-Tosetti, Craig J. Gibson & Sujith Dhanasiri. (2017) The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5. Oncology and Therapy 5:1, pages 31-40.
Crossref
Crossref
Chrissy H.Y. van Beurden-TanMargreet G. FrankenHedwig M. BlommesteinCarin A. Uyl-de GrootPieter Sonneveld. (2017) Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma. Journal of Clinical Oncology 35:12, pages 1312-1319.
Crossref
Crossref